A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Re-exposure After a Variable Interval and Subsequent Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed at Weeks 0, 2 and 4 Then Every 4 Weeks), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Been Withdrawn From Studies CDP870-031 or CDP870-032 Due to an Exacerbation of Crohn's Disease.
Каталог · ЕАЭС
Клинические исследования и проекты
UCB Pharma · найдено 23
23 исследования
Завершено
Фаза III
Россия
Certolizumab Pegol (CDP870) · UCB Pharma
Завершено
Фаза III
Россия
Keppra® extended release formulation - XR; Placebo · UCB Pharma
A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of Keppra® Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.
Завершено
Фаза III
Россия
Keppra XR (Levetiracetam XR) · UCB Pharma
An Open-label, Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Treatment of Partial-onset Seizures